U.S., May 9 -- ClinicalTrials.gov registry received information related to the study (NCT07575919) titled 'Targeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALL' on May 04.
Brief Summary: This is a single-center, open-label, single-arm prospective study designed to evaluate the safety, tolerability, and efficacy of dual-target CD22/CD19 chimeric antigen receptor (CAR)-T cell therapy as consolidation treatment in patients with standard-risk B-cell acute lymphoblastic leukemia (B-ALL) in remission. Eligible patients will undergo leukapheresis for CAR-T cell manufacturing, followed by lymphodepleting chemotherapy and CAR-T cell infusion. Patients will be closely monitored for safety, including cytokine release syndrome (CR...